| License revenue | 0 |
| Research and development | 8.93M |
| General and administrative | 2.77M |
| Total expenses | |
| Loss before other income | -11.7M |
| Interest income | |
| Other income, net | |
| Gain on warrant derivative liability | 246.21K |
| Gain on sale of affiliate's shares - RXi Pharmaceutical | |
| Loss before provision for income taxes | |
| Provision for income taxes | |
| Net income (loss) | -12.18M |
| Unrealized gain on available-for-sale securities | |
| Comprehensive income (loss) | |
| Basic net income (loss) per share (in dollars per share) | |
| Basic weighted average shares outstanding (in shares) | |
| Diluted net income (loss) per share (in dollars per share) | |
| Diluted weighted average shares outstanding (in shares) | |